Glycogen synthase kinase-3β inhibitors suppress leukemia cell growth

Experimental Hematology

Volumn 38, Issue 10, 2010, Pages

  Song, Emma Y ^a,b   Palladinetti, Patricia ^b   Klamer, Guy ^b   Ko, Kap Hyoun ^a,b   Lindeman, Robert ^b,c   O'Brien, Tracey A ^a,b   Dolnikov, Alla ^a,b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 6 BROMOINDIRUBIN 3' OXIME; 7 AMINODACTINOMYCIN; CASPASE 3; CD123 ANTIGEN; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INTERLEUKIN 3; INTERLEUKIN 3 RECEPTOR; LIPOCORTIN 5; LITHIUM CHLORIDE; PROTEIN BCL 2; QUERCETIN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

ANIMALIA;

EID: 77956601314     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.06.001     Document Type: Article

References (40)

1. Ougolkov A.V., Billadeau D.D. Inhibition of Glycogen Synthase Kinase-3. Wnt Signaling 2009, Humana Press, Clifton, NJ, p. 67-75.
2. Holmes T., O'Brien T.A., Knight R., Lindeman R., Symonds G., Dolnikov A. The role of glycogen synthase kinase-3b in normal haematopoiesis, angiogenesis and leukaemia. Curr Med Chem 2008, 15:1493-1499.
3. Frame S., Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001, 359:1-16.
4. Rayasam G.V., Tulasi V.K., Sodhi R., Davis J.A., Ray A. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 2009, 156:885-898.
5. Wang Z., Smith K.S., Murphy M., Piloto O., Somervaille T.C.P., Cleary M.L. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 2008, 455:1205-1209.
6. Cline G.W., Johnson K., Regittnig W., et al. Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. Diabetes 2002, 51:2903-2910.
7. Ring D.B., Johnson K.W., Henriksen E.J., et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 2003, 52:588-595.
8. Ougolkov A.V., Bone N.D., Fernandez-Zapico M.E., Kay N.E., Billadeau D.D. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 2007, 110:735-742.
9. Abrahamsson A.E., Geron I., Gotlib J., et al. Glycogen synthase kinase 3b missplicing contributes to leukemia stem cell generation. Proc Nat Acad Sci U S A 2009, 106:3925-3929.
10. Gustin J.P., Karakas B., Weiss M.B., et al. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Nat Acad Sci U S A 2009, 106:2835-2840.
11. Miyashita K., Kawakami K., Nakada M., et al. Potential therapeutic effect of glycogen synthase kinase 3b inhibition against human glioblastoma. Clin Cancer Res 2009, 15:887-897.
12. Ko K.-H., Odell R., Nordon R.E. Analysis of cell differentiation by division tracking cytometry. Cytometry Part A 2007, 71A:773-782.
13. Dennis G., Sherman B., Hosack D., et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biology 2003, 4:R60.
14. Huang D.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2008, 4:44-57.
15. Holmes T., O'Brien T.A., Knight R., et al. Glycogen synthase kinase-3b inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth. Stem Cells 2008, 26:1288-1297.
16. Lapidot T., Fajerman Y., Kollet O. Immune-deficient SCID and NOD/SCID mice models as functional assays for studying normal and malignant human hematopoiesis. J Mol Med 1997, 75:664-673.
17. Terui Y., Ikeda M., Tomizuka H., et al. Activated endothelial cells induce apoptosis in leukemic cells by endothelial interleukin-8. Blood 1998, 92:2672-2680.
18. Hazlehurst L.A., Dalton W.S. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metast Rev 2001, 20:43-50.
19. De Toni F., Racaud-Sultan C., Chicanne G., et al. A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene 2006, 25:3113-3122.
20. Matsunaga T., Takemoto N., Sato T., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003, 9:1158-1165.
21. Deng X., Ruvolo P., Carr B., May W.S. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc Nat Acad Sci U S A 2000, 97:1578-1583.
22. Wiseman A. Therapeutic-antagonists of oestrogens can be produced for cancer and other therapies using cytochromes P450 (CYP). Med Hypotheses 2005, 65:1088-1090.
23. Bauer S., Adrian N., Siebenborn U., et al. Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8. Cancer Immun 2009, 9:2.
24. Kaminska B., Wesolowska A., Danilkiewicz M. TGF beta signalling and its role in tumour pathogenesis. Acta Biochim Pol 2005, 52:329-337.
25. Park J., Kim K., Lee E.-J., et al. Elevated level of SUMOylated IRF-1 in tumor cells interferes with IRF-1-mediated apoptosis. Proc Nat Acad Sci U S A 2007, 104:17028-17033.
26. Dinarello C.A. The paradox of pro-inflammatory cytokines in cancer. Cancer Metast Rev 2006, 25:307-313.
27. Lawler J., Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 2004, 36:1038-1045.
28. Li B. Bone morphogenetic protein-Smad pathway as drug targets for osteoporosis and cancer therapy. Endocr Metab Immune Disord Drug Targets 2008, 8:208-219.
29. Hussain S.P., Harris C.C. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 1998, 58:4023-4037.
30. Rimon E., Sasson R., Dantes A., Land-Bracha A., Amsterdam A. Gonadotropin-induced gene regulation in human granulosa cells obtained from IVF patients: modulation of genes coding for growth factors and their receptors and genes involved in cancer and other diseases. Int J Oncol 2004, 24:1325-1338.
31. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008, 27:6207-6215.
32. Rinaudo M.S., Su K., Falk L.A., Halder S., Mufson R.A. Human interleukin-3 receptor modulates bcl-2 mRNA and protein levels through protein kinase C in TF-1 cells. Blood 1995, 86:80-88.
33. Jorgensen H.G., Allan E.K., Jordanides N.E., Mountford J.C., Holyoake T.L. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007, 109:4016-4019.
34. Guzman M.L., Swiderski C.F., Howard D.S., et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Nat Acad Sci U S A 2002, 99:16220-16225.
35. Osakada F., Takahashi M. Drug development targeting the glycogen synthase kinase-3b (GSK-3b)-mediated signal transduction pathway: targeting the Wnt pathway and transplantation therapy as strategies for retinal repair. J Pharmacol Sci 2009, 109:168-173.
36. Phelps R.A., Broadbent T.J., Stafforini D.M., Jones D.A. New perspectives on APC control of cell fate and proliferation in colorectal cancer. Cell Cycle 2009, 15:2549-2556.
37. Sato N., Meijer L., Skaltsounis L., Greengard P., Brivanlou A.H. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 2004, 10:55-63.
38. Staal F.J.T., Burgering B.M.T., van de Wetering M., Clevers H.C. TCF-1-mediated transcription in T lymphocytes: differential role for glycogen synthase kinase-3 in fibroblasts and T cells. Int Immunol 1999, 11:317-323.
39. Jin L., Lee E.M., Ramshaw H.S., et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor a chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009, 5:31-42.
40. Meijer L., Guyard N., Skaltsounis L., Eisenbrand G. Indirubin, the Red Shade of Indigo 2006, Life in Progress Editions, Roscoff, France.